SCHEMBL7080041

SCHEMBL7080041

C=C(c1cc(C(C)(C)C)cc2c1CCC2(C)C)c1sccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 19/20 0.56
RXRG P48443 11/20 0.41
RXRB P28702 11/20 0.41
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
RARB P10826 5/20 0.36
RARG P13631 4/20 0.36
RARA P10276 2/20 0.36
MEN1 O00255 1/20 0.36
CYP26A1 O43174 1/20 0.36
ABCB11 O95342 1/20 0.36
ESR1 P03372 1/20 0.36
PGR P06401 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083909 0.91 RXRA (0.56) RXRARXRGRXRBRARBRARG
SCHEMBL7081124 0.84 RXRA (0.53) RXRARXRGRXRB
SCHEMBL3633427 0.82 RXRA (0.65) RXRARXRGRXRBRARBRARG
SCHEMBL7088008 0.81 RXRA (0.61) RXRARXRGRXRBRARBRARG
SCHEMBL7080046 0.80 RXRA (0.53) RXRARXRGRXRBRARB
SCHEMBL7800113 0.80 RXRA (0.58) RXRARXRGRXRBRARBRARG
SCHEMBL7220989 0.77 RXRA (0.54) RXRARXRGRXRBRARBRARG
SCHEMBL29374183 0.76 RXRA (0.63) RXRARXRGRXRBKDM4EALDH1A1
SCHEMBL112943 0.76 RXRA (0.63) RXRARXRGRXRBKDM4EALDH1A1
SCHEMBL7080909 0.74 RXRA (0.62) RXRARXRGRXRBRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191145-A1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-09 US claimed
US-6534545-B1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-03-18 US claimed
US-6642273-B2 Dermatology, vision defects, cardiovascular disorders, antiinflammatory GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-11-04 US disclosed
US-20030191145-A1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-10-09 US disclosed
US-6534545-B1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191145-A1 Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics REL, DERL1, TLR7 RXRA 30/4885RXRG 77/4885RXRB 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.